Skip to content

Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)

Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030166
Enrollment
Unknown
Registered
2020-02-24
Start date
2020-02-25
Completion date
Unknown
Last updated
2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

The 5th Medical Center Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion of case criteria (pneumonia diagnosis and treatment protocol for COVID-19 (trial 6th edition)) 1. Common type patient: with fever, respiratory tract and other symptoms, and imaging findings of pneumonia. 2. Severe patients: patients who meet any of the following criteria (1) respiratory distress, RR>=30 times/min; (2) in resting state, oxygen saturation is less than 93%; (3) partial arterial oxygen pressure (PaO2)/oxygen absorption concentration (FiO2) =300mmHg (1mmHg = 0.133kpa); 3. TCM syndrome differentiation conforms to the clinical diagnostic criteria for patients in the early, middle, severe and convalescent stages of the pneumonia diagnosis and treatment program forCOVID-2019 (trial version 6); 4. Signed informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. The patient has other immune system, blood system, heart, liver, kidney and other important organs of the disease; 2. Accompanied by chronic diseases, such as malignant tumors, chronic obstructive pulmonary disease; 3. have a history of mental illness; 4. pregnant and nursing women; 5. less than 18 years old; 6. Studying drug allergies or contraindications; 7. Patients participating in other clinical trials; 8. The researchers consider other reasons not appropriate for clinical subjects.

Design outcomes

Primary

MeasureTime frame
CT scan of the lungs;Nucleic acid detection of throat secretion;

Secondary

MeasureTime frame
Body temperature;3CL Mpro of Coronavirus;Routine blood test;Routine urine test;Liver function test;Renal function test;

Countries

China

Contacts

Public ContactYanling Zhao

The 5th Medical Center Chinese PLA General Hospital

zhaoyl2855@126.com+86 13681208998

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026